- Conditions
- Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
- Interventions
- Rosiglitazone, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 53
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Normal Volunteers, Carnitine Palmitoyltransferase II Deficiency, Myopathic
- Interventions
- Intralipid/Heparin, Glycerol/Saline, Hyperinsulinemic euglycemic clamp
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
- Interventions
- Angiotensin-(1-7), Saline
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
- Interventions
- Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
- Drug
- Lead sponsor
- Kalie Tommerdahl
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Seattle, Washington
- Conditions
- Type 2 Diabetes
- Interventions
- Maximal ATP Production (ATPmax), Exercise Testing (VO2max), Muscle Biopsy, Adipose Tissue Biopsy, Hyperinsulinemic euglycemic clamp, PET imaging
- Other · Procedure
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Insulin Sensitivity
- Interventions
- Ultrasound, OGTT with unlabeled glucose and liver NMR, OGTT with carbon-13 labeled glucose and liver NMR, CGM glucose reading, HEC - Hyperinsulinemic-Euglycemic-Clamp
- Device · Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type I Diabetes Mellitus
- Interventions
- Glutamine, Placebo
- Dietary Supplement
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Diabetes
- Interventions
- Continous IV infusion of Nesiritide, Hyperinsulinemic euglycemic clamp, Placebo
- Drug
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Insulin Sensitivity
- Interventions
- 24h Continuous glucose monitoring and urinary C-peptide collection
- Device
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Diabetes (DM)
- Interventions
- Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Overweight and Obesity, Insulin Resistance, Metabolic Disease, Mitochondrial Metabolism, Sedentary Lifestyle
- Interventions
- Hyperinsulinemic-euglycemic Clamp
- Other
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 30 Years to 55 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon
- Conditions
- Diabetes Complications
- Interventions
- Epinephrine, Saline infusion
- Drug · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Insulin Resistance
- Interventions
- VO2 Max, DEXA, Peripheral Microvascular Reactivity, Skeletal Muscle Insulin Sensitivity, Non-Oxidative Glucose Disposal, Muscle tissue Biopsy
- Other
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Ischemic Cardiomyopathy, Hibernating Myocardium, Nerve; Disorder, Sympathetic
- Interventions
- Positron Emission Tomography
- Radiation
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Healthy Volunteers
- Interventions
- Nabilone, CP-945,598, hyperglycemic clamp, euglycemic-hyperinsulinemic clamp
- Other · Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes
- Interventions
- euinsulinemic euglycemic glucose clamp, euinsulinemic hyperglycemic glucose clamp, Hyperinsulinemic euglycemic glucose clamp, Hyperinsulinemic hyperglycemic glucose clamp
- Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus, Malignant Neoplasm
- Interventions
- assessment of therapy complications, laboratory biomarker analysis
- Procedure · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Polycystic Kidney Disease, Adult, Polycystic Kidney, Autosomal Dominant
- Interventions
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan
- Drug · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetic Kidney Disease, Type 1 Diabetes, Diabetes, Diabetes Mellitus, Diabetes Complications, Diabetic Nephropathies, Type1diabetes, Diabetes, Autoimmune, Autoimmune Diabetes, Juvenile Diabetes, Type 1 Diabetes Mellitus
- Interventions
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams/milliliter (mg/ml), PET/CT Scan, Renal Biopsy
- Drug · Radiation · Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Metabolic Syndrome
- Interventions
- Diagnostic exams
- Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 9 Years to 23 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hypertension
- Interventions
- DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
- Drug · Procedure
- Lead sponsor
- Wanpen Vongpatanasin
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Metabolism
- Interventions
- Overnight Metabolic Flexibility, Clamp Metabolic Flexibility
- Procedure
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- GDM, Lactation
- Interventions
- Hyperinsulinemic-euglycemic clamp
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Pediatric Obesity, Insulin Resistance, Dysglycemia, Hyperglycemia
- Interventions
- Hyperglycemic clamp, Hyperinsulinemic Euglycemic clamp
- Procedure
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida